MedMen Enterprises Competitors

MedMen Enterprises (OTCMKTS:MMNFF) and Abacus Health Products (OTCMKTS:ABAHF) are both medical companies, but which is the better business? We will compare the two companies based on the strength of their valuation, dividends, profitability, institutional ownership, risk, analyst recommendations and earnings.

Profitability

This table compares MedMen Enterprises and Abacus Health Products' net margins, return on equity and return on assets.

Earnings & Valuation

This table compares MedMen Enterprises and Abacus Health Products' gross revenue, earnings per share (EPS) and valuation.

Analyst Recommendations

This is a summary of recent ratings for MedMen Enterprises and Abacus Health Products, as reported by MarketBeat.com.

Acreage (OTCMKTS:ACRGF) and MedMen Enterprises (OTCMKTS:MMNFF) are both medical companies, but which is the better business? We will contrast the two businesses based on the strength of their risk, dividends, profitability, analyst recommendations, valuation, earnings and institutional ownership.

Analyst Recommendations

This is a breakdown of current recommendations for Acreage and MedMen Enterprises, as reported by MarketBeat.

Acreage presently has a consensus price target of $8.4333, indicating a potential upside of 204.45%. Given Acreage's stronger consensus rating and higher possible upside, research analysts clearly believe Acreage is more favorable than MedMen Enterprises.

Profitability

This table compares Acreage and MedMen Enterprises' net margins, return on equity and return on assets.

Valuation and Earnings

This table compares Acreage and MedMen Enterprises' top-line revenue, earnings per share (EPS) and valuation.

Summary

Acreage beats MedMen Enterprises on 3 of the 3 factors compared between the two stocks.

Applied Biosciences (OTCMKTS:APPB) and MedMen Enterprises (OTCMKTS:MMNFF) are both medical companies, but which is the better stock? We will compare the two companies based on the strength of their risk, institutional ownership, profitability, earnings, valuation, analyst recommendations and dividends.

Valuation and Earnings

This table compares Applied Biosciences and MedMen Enterprises' revenue, earnings per share and valuation.

Analyst Recommendations

This is a breakdown of recent ratings and recommmendations for Applied Biosciences and MedMen Enterprises, as reported by MarketBeat.

Profitability

This table compares Applied Biosciences and MedMen Enterprises' net margins, return on equity and return on assets.

MedMen Enterprises (OTCMKTS:MMNFF) and Ayr Strategies (OTCMKTS:AYRSF) are both medical companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, risk, earnings, dividends, analyst recommendations, institutional ownership and profitability.

Profitability

This table compares MedMen Enterprises and Ayr Strategies' net margins, return on equity and return on assets.

Analyst Ratings

This is a summary of recent ratings and price targets for MedMen Enterprises and Ayr Strategies, as reported by MarketBeat.

Ayr Strategies has a consensus price target of $34.8571, suggesting a potential upside of 63.96%. Given Ayr Strategies' stronger consensus rating and higher probable upside, analysts plainly believe Ayr Strategies is more favorable than MedMen Enterprises.

Earnings & Valuation

This table compares MedMen Enterprises and Ayr Strategies' gross revenue, earnings per share (EPS) and valuation.

Summary

Ayr Strategies beats MedMen Enterprises on 3 of the 3 factors compared between the two stocks.

Can B (NASDAQ:CANB) and MedMen Enterprises (OTCMKTS:MMNFF) are both medical companies, but which is the superior stock? We will compare the two companies based on the strength of their dividends, analyst recommendations, earnings, profitability, valuation, risk and institutional ownership.

Profitability

This table compares Can B and MedMen Enterprises' net margins, return on equity and return on assets.

Analyst Ratings

This is a breakdown of current ratings and target prices for Can B and MedMen Enterprises, as provided by MarketBeat.com.

Valuation and Earnings

This table compares Can B and MedMen Enterprises' top-line revenue, earnings per share (EPS) and valuation.

MedMen Enterprises (OTCMKTS:MMNFF) and Cansortium (OTCMKTS:CNTMF) are both medical companies, but which is the superior business? We will compare the two businesses based on the strength of their risk, profitability, dividends, institutional ownership, valuation, analyst recommendations and earnings.

Profitability

This table compares MedMen Enterprises and Cansortium's net margins, return on equity and return on assets.

Earnings and Valuation

This table compares MedMen Enterprises and Cansortium's gross revenue, earnings per share (EPS) and valuation.

Analyst Ratings

This is a breakdown of recent recommendations and price targets for MedMen Enterprises and Cansortium, as reported by MarketBeat.

Cansortium has a consensus target price of $1.20, suggesting a potential upside of 43.13%. Given Cansortium's stronger consensus rating and higher probable upside, analysts clearly believe Cansortium is more favorable than MedMen Enterprises.

Summary

Cansortium beats MedMen Enterprises on 3 of the 3 factors compared between the two stocks.